...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of experimental & clinical cancer research : >PARP inhibitors in gastric cancer: beacon of hope
【24h】

PARP inhibitors in gastric cancer: beacon of hope

机译：胃癌中PARP抑制剂：希望灯塔

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Defects in the DNA damage response (DDR) can lead to genome instability, producing mutations or aberrations that promote the development and progression of cancer. But it also confers such cells vulnerable to cell death when they inhibit DNA damage repair. Poly (ADP-ribose) polymerase (PARP) plays a central role in many cellular processes, including DNA repair, replication, and transcription. PARP induces the occurrence of poly (ADP-ribosylation) (PARylation) when DNA single strand breaks (SSB) occur. PARP and various proteins can interact directly or indirectly through PARylation to regulate DNA repair. Inhibitors that directly target PARP have been found to block the SSB repair pathway, triggering homologous recombination deficiency (HRD) cancers to form synthetic lethal concepts that represent an anticancer strategy. It has therefore been investigated in many cancer types for more effective anti-cancer strategies, including gastric cancer (GC). This review describes the antitumor mechanisms of PARP inhibitors (PARPis), and the preclinical and clinical progress of PARPis as monotherapy and combination therapy in GC.
机译：DNA损伤响应（DDR）中的缺陷可导致基因组不稳定性，产生促进癌症发展和进展的突变或像差。但是当它们抑制DNA损伤修复时，它还赋予这种细胞易患细胞死亡。聚（ADP-核糖）聚合酶（PARP）在许多细胞过程中起着核心作用，包括DNA修复，复制和转录。当DNA单链断裂（SSB）发生时，PARP诱导聚（ADP-核糖基化）（氨基化）的发生。 PARP和各种蛋白质可以通过粉状直接或间接地相互作用以调节DNA修复。已发现直接靶标PARP的抑制剂阻断SSB修复途径，引发同源重组缺陷（HRD）癌症以形成代表抗癌策略的合成致死概念。因此，已经在许多癌症类型中进行了研究，以获得更有效的抗癌策略，包括胃癌（GC）。该综述描述了PARP抑制剂（PARPI）的抗肿瘤机制，以及Parpis作为GC中单药治疗和联合治疗的临床前和临床进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号